Patent · US Active

(R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity

US11267804B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Patrick René Angibaud · Louviers, FR
Olivier Alexis Georges Querolle · Évreux, FR
Didier Jean-Claude Berthelot · Edegem, BE
Christophe Meyer · Oissel, FR
Matthieu WILLOT · Goldkronach, DE
Lieven Meerpoel · Beerse, BE
Thierry Francois Alain Jean Jousseaume · Schaffhausen, CH

Key dates

Filing date	Nov 12, 2019
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Nov 12, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/10
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.